Mycobacterium szulgai pulmonary infection in a vitamin D–deficient patient: A case report

Hadi Lotfi1,2 | Mojtaba Sankian3 | Zahra Meshkat1,2 | Ahmad Khalifeh Soltani4 | Ehsan Aryan1,2

1Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2Department of Medical Microbiology, Ghaem University Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
3Immunobiochemistry Laboratory, Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract
Closer attention should be paid to vitamin D status in patients with mycobacterial diseases.

Keywords
case report, Mycobacterium szulgai, pulmonary infection, vitamin D deficiency

1 | BACKGROUND

Mycobacterium szulgai (M szulgai) is an opportunistic and rare pathogen. Several risk factors play roles in the development of disease caused by this bacterium including immunodeficiency syndromes, previous Mycobacterium tuberculosis infection, and smoking. We reported a case of M szulgai respiratory infection in a 32-year-old male patient without any history of smoking, immunodeficiency syndromes or receiving immunosuppressive medications but the patient was severely deficient in vitamin D. Finally, the following treatment regimen was administered to the patient: isoniazid, rifampin, ethambutol, clarithromycin antimicrobial agents supplemented with vitamin B6 and vitamin D. The patient's clinical condition was improved after 10 months of treatment.

Vitamin D deficiency should be considered as a risk factor for M szulgai pulmonary infection in immunocompetent people who are daily exposed to very little sunlight due to weather, occupational, or religious reasons.

Nontuberculous mycobacteria (NTM) are widespread worldwide. These bacteria can be transmitted to humans from environmental sources such as soil and water with no reported cases of person-to-person transmission.1

Mycobacterium szulgai is a slow-growing NTM and a rare human pathogen, representing <0.2% of all NTM infections.2 Mycobacterium szulgai pulmonary infections are infrequently reported in those with a history of chronic obstructive pulmonary disease (COPD), tuberculosis, or immunosuppression.3 Clinically, it is indistinguishable from Mycobacterium tuberculosis infection and neoplasm; therefore, it is critical
to be diagnosed accurately.\textsuperscript{4} Moreover, there is no consensus recommendation for treatment of \textit{M szulgai} infections, probably due to its low prevalence.\textsuperscript{5} Herein, we present a case of \textit{M szulgai} pulmonary infection in an immunocompetent patient without any history of tuberculosis or consumption of immunosuppressive drugs but severely deficient in vitamin D that was successfully treated in Mashhad, Iran.

\section{CASE PRESENTATION}

A 32-year-old man was referred to Ghaem Hospital affiliated to Mashhad University of Medical Sciences in February 2019 with symptoms of night sweats, cough, and chest pain with previous pulmonary infection \textit{mycobacterium tuberculosis} diagnosis based on positive acid-fast bacilli smear test. Tuberculosis was diagnosed in August 2016. The patient was received a standard 6-month regimen including rifampin, isoniazid, ethambutol, and pyrazinamide. After the treatment, the result sputum smear and culture for acid-fast were negative. He had no history of alcohol use and smoking. The patient had a weight loss of 9 kg over 1 year. The patient worked in a clothing industry that was not exposed to sunlight. An initial test performed on the patient showed severe vitamin D deficiency. A serology test for HIV was negative. The chest X-ray revealed an increase in pleural thickness was seen in the left lung and less strongly in the right lung. Reticular lesions were observed in the field of lungs, specifically, at the top of the lungs (Figure 1A). High-resolution computed tomography (HRCT) revealed bronchiectasis, distractive changes, and multiple cysts with collapse in the left upper lobe. Bronchiectasis and cyst formation with tree-in-bud pattern were observed in the right upper lobe and less intensively in the right middle lobe and upper left lower lobe segment and with less intensity in the upper right lobe (Figure 1C). Laboratory findings (Table 1) combined with the clinical signs of the patient raised the possibility of \textit{Mycobacterium tuberculosis} infection (TB). Therefore, direct smear microscopy for acid-fast bacilli (AFB) and mycobacterial culture were performed on the patient’s sputum sample. All three samples obtained from the patient were smear-positive for AFB using Ziehl-Neelsen method. Also, mycobacterial culture of the patient’s samples on Lowenstein-Jensen medium became positive for AFB 22 days after inoculation. To identify the grown bacterium, two independent PCR assays were performed on the DNA extracted from the bacterial colonies. One PCR assay had been designed to detect IS\textit{6110}, a specific gene target for \textit{M tuberculosis} complex, in the specimen and the other assay detected \textit{rpoB}, a mycobacterium genus-specific target. The organism was identified as (NTM) due to obtaining negative and

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Thirty-two-year-old man with \textit{M szulgai} respiratory infection. A, Fibrotic changes in the lungs with preference to the left lung. B, Follow-up chest radiograph 10 mo after treatment. C, Bronchiectasis and cyst formation with a tree-in-bud pattern in the right upper lobe and less strongly in the right middle lobe and upper left lower segments.}
\end{figure}
positive results, respectively, for the former and the latter PCR assays. Results were also confirmed by sequencing of the ITS (16S-23S) (accession number MN124505), rpoB (accession number MN158122), and hsp65 (accession number MN158123) genes of M szulgai. Based on the drug susceptibility test (DST) results, treatment with isoniazid (225 mg), rifampicin (450 mg), ethambutol (825 mg), clarithromycin (1000 mg), vitamin B6 (10 mg), and vitamin D (900 IU) oral daily was started. After 10 months of treatment, a sputum sample was taken from the patient, smear, and culture tests were negative. Chest pain and dyspnea were resolved and the patient gained 6 kg. Significant improvement was seen in the chest X-ray (Figure 1B). The patient’s serum vitamin D also reached normal.

3 | DISCUSSION

According to the ATS (American thoracic society) and IDSA (infectious disease society of America) guidelines released in 2007, to identify NTM respiratory infection radiological, microbiological, and clinical findings are required. These include finding nodular or cavitary lesions on chest X-ray or bronchiectasis on HRCT and positive culture of at least two sputum specimens. Most cases of M szulgai respiratory infection have been previously reported to be fibrocavitary, whereas in our case, most lesions were in the upper lobe. Lio et al showed that the bronchiectasis form of Mycobacterium avium pulmonary infection is more commonly seen in those with chronic obstructive pulmonary disease or gastrointestinal malfunctions such as gastroesophageal reflux disease. Our patient had no history of any obstructive diseases or gastrointestinal malfunctions. In the majority of reported cases, M szulgai respiratory infections men over 50 years of age and have risk factors such as alcohol abuse, smoking, history of TB infection, low body mass index, or skeletal abnormalities of the chest. To our knowledge, the present patient is the youngest case of M szulgai pulmonary infection without any underlying disease with had severe vitamin D deficiency. Vitamins can affect different components of the innate immune system, and deficiencies lead to defects in the immune system and infections. The normal blood level of vitamin D is about 30 ng/mL, and vitamin D deficiency involves a blood level below 20 ng/mL. Douglas et al demonstrated that vitamin D plays an important role in immunological defense against mycobacterial infections. Vitamin D activates macrophages by blocking the intracellular growth of mycobacteria; on the other hand, vitamin D deficiency causes immune system defeat and growth Mycobacteria easily. The main source of vitamin D for humans is sunlight. Because the patient spent a lot of time at the workplace and no history of eating vitamin D supplements and vitamin D rich diets, he had a severe vitamin D deficiency.

Unlike other NTM, M szulgai is sensitive to most anti-TB drugs and responds well to treatment regimens containing more than two anti-TB drugs. Mycobacterium szulgai is also sensitive to macrolides, aminoglycosides, and fluoroquinolones. In some reports, clarithromycin treatment with ethambutol and rifampicin or rifabutin has been found effective. Clarithromycin is one of the famous members of aminoglycosides which has been FDA approved in 1990. This therapeutic agent is recommending for various bacterial infection particularly mycobacterial diseases. According to review of the literatures, there are several evidence for successful treatment of clarithromycin in pulmonary infection caused by M szulgai. On a 10-month follow-up, the patient had a negative smear and culture. Signs of improvement in the patient's chest X-ray visible (Figure 1B).

4 | CONCLUSION

Mycobacterium szulgai can infect immunocompetent individuals with risk factors such as vitamin D deficiency. Considering the positive effect of vitamin D on innate immunity through the regulation of macrophage activation, supplementing regimens are highly recommended for the
treatment of NTM infections. Closer attention should be paid to vitamin D status in patients with mycobacterial diseases.

ACKNOWLEDGMENT
Consent statement: Published with written consent of the patient.

CONFLICT OF INTEREST
None declared.

AUTHOR CONTRIBUTION
HL: carry out the laboratory experiments and the acquisition of data. HL, MS, and EA: wrote the first draft of the manuscript. AKS: contributed to revise the article critically for important intellectual content. ZM, HL, and EA: collaboratively contributed to the concept of the original research resulted in this report. All authors reviewed and approved the final version of the manuscript.

ETHICAL APPROVAL
Ethical approval to report this case was obtained from Mashhad University of Medical Sciences Regional Ethics Committee, Mashhad University of Medical Sciences, Mashhad, Iran (Approval Number: IR.MUMS.fm.REC.1396.638).

DATA AVAILABILITY STATEMENT
The data that support the findings of this case are available from the corresponding author (Ehsan Aryan), upon reasonable request.

ORCID
Hadi Lotfi https://orcid.org/0000-0002-6357-0911
Mojtaba Sankian https://orcid.org/0000-0001-5373-4866
Zahra Meshkat https://orcid.org/0000-0002-4032-7599
Ehsan Aryan https://orcid.org/0000-0002-1966-8065

REFERENCES
1. Gido RDS, Wojciechowski AL, Bajwa RP. Pulmonary infection with Mycobacterium szulgai: a case report. SAGE Open Med Case Rep. 2019;7:2050313X18823448.
2. Martín-Casabona N, Bahrami AR, Bennedsen J, et al. Nontuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis. 2004;8(10):1186-1193.
3. Marks J, Jenkins P, Tsukamura M. Mycobacterium szulgai—a new pathogen. Tubercle. 1972;53(3):210-214.
4. Khan S, Clerk N, Galloway K, Mustafa R, Antunes G. Pulmonary Mycobacterium szulgai infection: a case report. QJM. 2016;109(7):489-490.
5. Sánchez-Alarcos JM, De Miguel-Diez J, Bonilla I, Sicilia JJ, Alvarez-Sala JL. Pulmonary infection due to Mycobacterium szulgai. Respiration. 2003;70(5):533-536.
6. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416.
7. Lio J, Lee Y, Obata R. Comparison of characteristics of fibrocavitary and bronchiectasis phenotypes of pulmonary Mycobacterium avium, in A106. NTM: BENCH TO BEDSIDE. Am Thorac Soc. 2019;199:A2524.
8. Lake MA, Ambrose LR, Lipman MCI, Lowe DM. “Why me, why now?” Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. BMC Med. 2016;14(1):54.
9. Erickson KL, Medina EA, Hubbard NE. Micronutrients and innate immunity. J Infect Dis. 2000;182(Supplement_1):S5-S10.
10. Fischer J, Ganellin CR. Analogue-Based Drug Discovery. Hoboken, NJ: Wiley-VCH; 2010.
11. Basile D, Jounieux V, Andréjak C. Treatment of other nontuberculous mycobacteria. Semin Respir Crit Care Med. 2018;39(03):377-382.

How to cite this article: Lotfi H, Sankian M, Meshkat Z, Khalifeh Soltani A, Aryan E. Mycobacterium szulgai pulmonary infection in a vitamin D-deficient patient: A case report. Clin Case Rep. 2021;9:1146–1149. https://doi.org/10.1002/ccr3.3692